Irit Yaniv, MD, MBA
4 Carmeli Street, Ramat Chen, Israel
Mobile: 054-234 7771
Dr. Yaniv is an experienced and accomplished and senior executive in the life sciences industry Dr.
Yaniv is deeply involved in the life-science eco-system as a well-respected manager, entrepreneur, investor and mentor. Presently, she is a partner at one of the best medical device investment funds in Israel, Accelmed.
Being part of the eco-system, Dr. yaniv dedicates time to dynamically contribute to international conferences such as the BioMed and ICI being held on a yearly basis in Israel.
Dr. Yaniv has an international extensive network that support and expand the fund activities; the network includes strong Chinese affiliations, as well as USA and European connections.
Dr. Yaniv provides, beyond technical competence and sound judgment, a “quality manager” with a strong network who is both admired and respected by the staff, management, boards, investors and peers.
1981 –1989: MD, Medical School, Ben Gurion University, Beer-Sheva, Israel
2004 –2005: MBA, EMBA program, Recanati School, Tel-Aviv.
2020 – Present
Establishing Almeda Ventures
In process of establishing a public ventures fund focusing in Healthtech Investments, specifically in Digital health field.
Co-Founder of WE@HealthTech Program
A Healthtech launchpad program to promote junior women managers to executive positions throughout the ecosystem.
2012 – 2020 (www.accelmed.co.il)
General partner @ U. Geiger Investments Management Ltd. (for Accelmed)
Accelmed is an investment firm focused on value creation for medical device companies and technologies. Irit is managing the innovation hub (Targeted Innovation Program), with an
executive role (chairperson or board member) in all of the Portfolio of the Ventures fund I companies, including: Valcare Medical, Sonivie, Eximo Medical, Digma Medical, Memic and others.
During this period –
• Most of the companies raised additional funds at a higher valuation than previous rounds;
• Eximo, in which Irit acts as the chairperson, was acquired by Angiodynamics –
• Another 2 companies (one is Endospan and one is undisclosed), in which Irit is part ofthe BOD, had signed a structural acquisition agreement with major Multi-national
• Digma Medical Ltd. – developing treatment for Type 2 DM
o Company reached a clinical stage with very promising results
• NitiNotes Ltd. – developing a minimal invasive procedure to treat obesity
o Company reached a clinical stage
2011 – 2012 Impulse Dynamics NV;
2007 – 2011 Metacure Limited
• Position Chief Executive Officer
Both companies are part of Prof. Ben Haim Medical Group; Companies developed novel implanted systems based on Non-Excitatory Stimulation; while Impulse targeting CHF patients, Metacure is focusing on Diabetes and Obesity.
Manage both organizations in North America, Europe and Israel.
MetaCure – Driving the company from the research phase to a commercially mature company by establishing a high level of awareness and acceptance for Interventional Diabetology in the market space.
Company was shut down apporx. 2 yrs post Irit’s leaving.
Impulse – Dynamics – Growing and stabilized the European sales organization; developed the product road map for the near future and implemented this new arena into the heart failure clinics rather than hospitals, as before.
Company is currently in commercial stage.
2005 –2007 BrainsGate Ltd.
Brainsgate is a medical device company committed to developing a novel treatment modality, electrical SPG stimulation
• Position: VP Clinical Affairs & Head of the Ischemic Stroke Application Development
Established the preclinical and clinical research strategy for the Stroke application towards the first human studies.
Successfully managed the Stroke Scientific Advisory Board to support and efficiently execute the human studies.
Designed and supervised the first human studies with the System in India and Europe, together with the clinical department.
2004- 2005 BSP –Biological Signal Processing Ltd.
BSP is dedicated to providing novel, non-invasive and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease.
Position: VP Clinical and Business Development
Developed the product concept from inception through launch. Achieved regulatory approvals in form of 510K.
Interfaced with, and raise capital from, venture capitalists and companies specializing in life sciences.
1998 –2004 Sunlight Medical Ltd.
Sunlight (today, BeamMed) devices are radiation-free, user-friendly technologies, such as quantitative ultrasound, to provide services that fit physicians’ needs, are marketed both to small practices and to hospitals.
• Position: Executive Vice President Research, Development & Regulatory
Gained FDA approval for all products, in forms of PMA and 510K. Lead the R&D team and launched new products into the market space; using acquired or internal developed technologies. Launched the product/s in different markets including US, Asia (China, Korea) and Europe.
1994 – 1998 Bayer / Pharma Clinical Ltd.– Israel
• Position: Clinical Project Leader – Responsibilities – Anti Infective Diseases and Dermatology trials.
Coordinated the anti-infective and dermatology clinical program of Bayer’s international and multi-center national studies performed in Israel.
Born on 1964,
1990 to 1994: Served as an Army General Physician at the Israeli Defense Forces
2009-2015 A board member in IATI (www.iati.com)
The Israeli Advanced Technology Industries (IATI) is the largest umbrella organization representing the high tech
and life science industries.
Mentoring in the Microsoft Accelerator Program
Actively participating in the BioMed and ICI program – e.g. start up competition; medical device program; digital
Participating in 8400 program – second cohort
Completed an executive program in Harvard Business School
Widely published and has several papers/posters/presentations addressing the effectiveness of drugs, delivery methods and disease progression.
1. Epidemiology of invasive Haemophilus influenzae type b infections in Bedouins and Jews in southern Israel.
Halfon-Yaniv I, Dagan R. – Pediatr Infect Dis J 1990 May;9(5):321-6
2. Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review.
Segev S, Yaniv I, Haverstock D, Reinhart H. – Clin Infect Dis 1999 Feb;28 (2):299-308
3. Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women.
Raz R, Naber KG, Raizenberg C, Rohana Y, Unamba-Oparah I, Korfman G, Yaniv I. – Eur J Clin Microbiol
Infect Dis 2000 May;19(5):327-31
4. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children.
Leibovitz E, Janco J, Piglansky L, Press J, Yagupsky P, Reinhart H, Yaniv I, Dagan R. – Pediatr Infect Dis J 2000
5. North American Male Referance Population for Speed of sound (SOS) in Bone at Multiple skeletal Sites.
SR Hayman1, W Drake, DL kendler, WP Olszynski, JD Adachi, CE Webber, CJ Rosen, HK Genant, E Orwoll, I yaniv, LE Pickard – J Clin Densitom 2002 Spring;5(1):63-71
6. The effects of alendronate in postmenopausal women with osteoporosis. Yaniv I. Osteoporos Int. 2003 Jan; 14(1): 90-1
7. Bone density in axial and appendicular skeleton in patients with lactose intolerance: influence of calcium intake and vitamin d status. Segal E, Dvorkin L, Lavy A, Rozen GS, Yaniv I, Raz B, Tamir A, Ish-Shalom S. – J Am Coll Nutr. 2003 Jun;22(3):201-7.
8. Longitudinal Monitoring of Bone Accretion measured by Quantitative multi-site ultrasound of bones in patients with delayed puberty (a pilot study). Z. Zadik, T. Sinai, E. Borondukov, A. Zung, I. Yaniv, R. Reifen ; Osteoporosis International 2004 Dec 23
9. Assessment of skeletal age at the wrist in children with a new ultrasound device.
Mentzel HJ, Vilser C, Eulenstein M, Schwartz T, Vogt S, Bottcher J, Yaniv I, Tsoref L, Kauf E, Kaiser WA.
Pediatr Radiol. 2005 Apr;35(4):429-433. 2005 Feb 24.
10. Quantitative ultrasound in the evaluation of bone status in premature and full-term infants.
Teitelbaum JE, Rodriguez RJ, Ashmeade TL, Yaniv I, Osuntokun BO, Hudome S, Fanaroff A. J Clin Densitom.
2006 Jul-Sep;9(3):358-62. Epub 2006 May 11.
11. Normal DXA Bone Mineral Density but Frail Cortical Bone in Turner’s Syndrome. Nehama Zuckerman-
Levin*, Irit Yaniv†, Tseela Schwartz†, Hadassah Guttmann* and Ze’ev Hochberg; Clinical Endocrinology
12. Treatment of Type 2 Diabetes Using Meal-Triggered Gastric Electrical Stimulation
Shai Policker BSc MBA, Walid Haddad PhD and Irit Yaniv MD MBA. Israeli Medical Association Journal
(IMAJ), VOL 11,April 2009
13. Fasting plasma triglycerides predict the glycaemic response to treatment of Type 2 diabetes by gastric
electrical stimulation. A novel lipotoxicity paradigm . H. Lebovitz, B. Ludvik, I. Yaniv, W. Haddad, T. Schwartz,
R. Aviv and the MetaCure Investigator Group. Diabetic Medicine, Accepted manuscript online: 16 JAN 2013
14. Gastric electrical stimulation treatment of type 2 diabetes: effects of implantation versus meal-mediated
stimulation. A randomized blinded cross-over trial. Lebovitz HE, Ludvik B, Kozakowski J, Tarnowski
W, Zelewski M, Yaniv I, Schwartz T. Physiol Rep. 2015 Jul 14;3(7). Epub 2015 Jul 14.
15. Treatment of Patients with Obese Type 2 Diabetes with Tantalus-DIAMOND® Gastric Electrical Stimulation:
Normal Triglycerides Predict Durable Effects for at Least 3 Years. Lebovitz HE, Ludvik B, Yaniv I, Schwartz T,
Zelewski M, Gutterman DD; Metacure Investigators. Horm Metab Res. 2015 Jun;47(6):456-62. doi: 10.1055/s-
0035-1548944. Epub 2015 Apr 16.
• Gastrointestinal electrical therapy – WO 2011092710
• Method of treating a patient – US 8738127
• Methods and systems for reducing neural activity in an organ of a subject – WO 2014118782
• Endoluminal sleeve gastroplasty – WO 2015052720
Posters and Oral Presentation:
• TEMPRATURE EFFECT ON SPEED OF SOUND MEASUREMENTS AT THE THIRD PROXIMAL PHALANX / Irit
Yaniv, Tseela Schawrtz, Yehuda Niv.; China 1999
• SOS AND BMD T-SCORES OF LOW TRAUMA FRACTURED WOMEN: THE WHO CRITERIA AS APPLIED TO
OSTEOPOROTIC PATIENTS / S. Ish-Shalom1, I. Yaniv, C. Singal, Y. Niv; China 1999
• PREDICTION OF FEMORAL FAILURE LOAD FROM FEMORAL BMD AND ULTRASONIC VELOCITY AT THE
FEMUR, RADIUS AND PHALANX./ M.L.Bouxsein1, P.H.F.Nicholson, D.M.Rossler, S.Ashkenazi, I.Yaniv;
• UPDATE IN DIAGNOSIS OF OSTEOPOROSIS; QUANTITATIVE ULTRASOUND TECHNIQUES –SUNLIGHT
OMNISENSE IN THE MANAGEMENT OF OSTEOPOROSIS / Yaniv- Korea 1999
• LATE CATCH-UP OF BONE STRENGTH IN PREMATURELY BORN CHILDREN-PRELIMINARY RESULTS / Z Zadik,
A Shamaev, D Geva, I Yaniv. – ISCD – Rio, Brazil, 2000
• OSTEOPOROSIS RISK INDEX™ (ORI™): COMBINED MULTI-SITE MEASUREMENTS FOR BETTER
OSTEOPOROTIC FRACTURES. / I Yaniv, M Weiss, D Geva, A Ben-Shlomo, P. Hagag, Y Niv.- ASBMR 2000
• ESTABLISHMENT OF PEDIATRIC REFERENCE CURVE FOR SUNLIGHT OMNISENSE 7000P / Geva D, Zadik
M, Cho C, Schwarts T, Yaniv I. – ASBMR 2001
• LONGITUDINAL MONITORING OF BONE DEVELOPMENT MEASURERD BY QUANTITATIVE
ULTRASOUND OF BONES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE / Z. Zadik,
D. Prais, I. Yaniv, A. Kattan – Presented 2003
• HOW TO PREDICT FRACTURE PROPENSITY IN TURNER SYNDROME? / . Zuckerman-Levin,
I. Yaniv, T. Schwartz, H. Guttmann, Z. Hochberg – Presented 2003
• QUANTATITATIVE ULTRASOUND MEASUREMENT OF THE SPEED OF SOUND IN THE BONE OF CHILDREN
AND ADOLESCENTS / H.-J. Mentzel, A. Malich, U. John, T. Schwartz, J. B צttcher, S. Vogt, I. Yaniv, J.
Misselwitz, W.A. Kaiser – Presented 2004
• ULTRASOUNIC BONE AGE ASSESSMENT IN CHILDREN / Z. Zadik, A Zung, E. Borondukov, I. Yaniv – Presented 2004
Irit Yaniv 6
CV – 2020
• AN INNOVATIVE ULTRASONIC METHOD FOR BONE AGE ASSESSMENT OF ISRAELI AND CHINESE CHILDREN
/ J. Yu, Z. Zadik, A. Golander, T. Bistritzer, I. Yaniv, L. Tsoref, T. Schwartz – Presented 2004
• ASSESSMENT OF SKELETAL AGE IN CHILDREN AND ADOLESCENTS USING RADIUS SONOGRAPHY IN COMPARISON TO
STANDARDISED RADIOGRAPHY / H.J. Mentzel, C. Vilser, M. Eulenstein, T. Schwartz, J. Bottcher, S. Vogt, I. Yaniv, E. Kauf, W.A. Kaiser – Presented 2004
• ASSESSING BONE AGE IN CHILDREN WITH DELAYED DEVELOPMENT USING ULTRASOUND / Z. Zadik, T. Bistritzer, T. Schwartz, L. Tsoref, I. Yaniv – Presented 2004